Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study

YORGUN, HIKMET; CANPOLAT, Uğur; Özer, Necla; Elibol, Bulent

Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study

Necla ÖZER, (Hacettepe Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Hikmet YORGUN, (Hacettepe Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Uğur CANPOLAT, (Hacettepe Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Bülent ELİBOL (Hacettepe Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, Ankara, Türkiye)

Anadolu Kardiyoloji Dergisi

0 0

Yıl: 2014 Cilt: 14 Sayı: 2 Sayfa Aralığı: 121 - 127 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study

Öz:

Objective: In this study, we aimed to evaluate the impact of cabergoline use in patients with Parkinson’s disease on valvular and biventricular functions. Methods: In this observational cohort study, patients with Parkinson disease were divided into 2 groups as 34 patients (41.2% female, age; 57.4±15.3 years) using cabergoline (Group 1) and 42 patients (61.9% female, age; 53.7±7.1 years) not using cabergoline (Group 2). In addition to conventional echocardiography and diastolic functions, tissue Doppler imaging was used to evaluate both global and regional systolic - dia- stolic functions. Correlations were assessed using Pearson correlation coefficient for normally distributed variables. Results: In group 1 patients cabergoline was used for 7.7±5.1 years and mean and cumulative cabergoline dose were 3.3±1.1 mg and 9.8±7.0 g respectively. Left ventricular systolic functions and tissue Doppler measurements of septal and lateral mitral annulus and right ventricular systolic and diastolic velocities were similar between groups. Mitral valve tenting area was significantly higher in patients using cabergoline (p=0.007). The association between cumulative cabergoline dose and diastolic functions was also evaluated which revealed that among dia- stolic function parameters, Epeak (r=0.253, p=0.042), E/A (r=0.256, p=0.026) and DT (r=-0.382, p=0.001) were correlated with cumulative cabergo- line dose. There was a positive correlation between cumulative cabergoline dose and duration of cabergoline therapy with composite regurgi- tation score (r=0.435, p<0.001; r=0.485, p<0.001, respectively). Conclusion: Our findings indicated that despite the well known effects of cabergoline on valvular functions, we did not observe any alteration in systolic functions, but diastolic functions which was associated with cumulative cabergoline dose in patients with Parkinson’s disease. (Anadolu Kardiyol Derg 2014; 14: 121-7)

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr, et al. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63: 301-4. [CrossRef] 2. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19: 656-62. [CrossRef] 3. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-42. [CrossRef] 4. Müller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 2003; 26: 109-11. [CrossRef] 5. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B, et al. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002; 161: 2111-21. [CrossRef] 6. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-83. [CrossRef] 7. Gustafsson BI, Tømmerås K, Nordrum I, Loennechen JP Brunsvik , A, Solligård E, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005; 111: 1517-22. [CrossRef] 8. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P Hanoun N, , Lanfumey L, et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006; 113: 81-9. [CrossRef] 9. Gulati VK, Katz WE, Follansbee WP Gorcsan J 3rd. Mitral annular , descent velocity by tissue Doppler echocardiography as an index of global left ventricular function. Am J Cardiol 1996; 77: 979-84. [CrossRef] 10. Kaya EB, Özer N, Aksoy H, Deveci OS, Tülümen E, Okutucu S, et al. Mean systolic annular velocity and strain score index: new and non-invasive parameters for the evaluation of acute myocardial infarction patients. Anadolu Kardiyol Derg 2010; 10: 239-46. [CrossRef] 11. Rasmussen VG, Poulsen SH, Dupont E, Ostergaard K, Safikhany G, Egeblad H, et al. Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking. Eur J Echocardiogr 2008; 9: 803-8. [CrossRef] 12. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15: 167-84. [CrossRef] 13. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16: 777-802. [CrossRef] 14. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther 2011; 29: 404-10. [CrossRef] 15. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46. [CrossRef] 16. Nagueh SF, Appleton CP Gillebert TC, Marino PN, Oh JK, Smiseth , OA. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107-33.[CrossRef] 17. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine- agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6: 826-9. [CrossRef] 18. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006; 67: 1225-9.[CrossRef] 19. Peralta C, Wolf E, Alber H, Seppi K, Müller S, Bösch S, et al. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord 2006; 21: 1109-13. [CrossRef] 20. Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord 2009; 24: 129-33. [CrossRef] 21. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002; 303: 815-22. [CrossRef] 22. Cordoba-Soriano JG, Lamas-Oliveira C, Hidalgo-Olivares VM, Tercero-Martinez A, Barambio-Ruiz M, Salas-Nieto J. Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline. Rev Esp Cardiol 2013.Epub ahead of print.

APA	Özer N, YORGUN H, CANPOLAT U, Elibol B (2014). Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. , 121 - 127.
Chicago	Özer Necla,YORGUN HIKMET,CANPOLAT Uğur,Elibol Bulent Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. (2014): 121 - 127.
MLA	Özer Necla,YORGUN HIKMET,CANPOLAT Uğur,Elibol Bulent Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. , 2014, ss.121 - 127.
AMA	Özer N,YORGUN H,CANPOLAT U,Elibol B Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. . 2014; 121 - 127.
Vancouver	Özer N,YORGUN H,CANPOLAT U,Elibol B Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. . 2014; 121 - 127.
IEEE	Özer N,YORGUN H,CANPOLAT U,Elibol B "Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study." , ss.121 - 127, 2014.
ISNAD	Özer, Necla vd. "Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study". (2014), 121-127.

APA	Özer N, YORGUN H, CANPOLAT U, Elibol B (2014). Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Anadolu Kardiyoloji Dergisi, 14(2), 121 - 127.
Chicago	Özer Necla,YORGUN HIKMET,CANPOLAT Uğur,Elibol Bulent Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Anadolu Kardiyoloji Dergisi 14, no.2 (2014): 121 - 127.
MLA	Özer Necla,YORGUN HIKMET,CANPOLAT Uğur,Elibol Bulent Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Anadolu Kardiyoloji Dergisi, vol.14, no.2, 2014, ss.121 - 127.
AMA	Özer N,YORGUN H,CANPOLAT U,Elibol B Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Anadolu Kardiyoloji Dergisi. 2014; 14(2): 121 - 127.
Vancouver	Özer N,YORGUN H,CANPOLAT U,Elibol B Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Anadolu Kardiyoloji Dergisi. 2014; 14(2): 121 - 127.
IEEE	Özer N,YORGUN H,CANPOLAT U,Elibol B "Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study." Anadolu Kardiyoloji Dergisi, 14, ss.121 - 127, 2014.
ISNAD	Özer, Necla vd. "Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study". Anadolu Kardiyoloji Dergisi 14/2 (2014), 121-127.